Today: 29 April 2026
Infineon stock price slips again before Feb. 4 results — what traders watch next
1 February 2026
1 min read

Infineon stock price slips again before Feb. 4 results — what traders watch next

FRANKFURT, Feb 1, 2026, 00:52 (CET) — Market closed

  • Infineon slipped 0.45% on Friday, following a steeper decline the previous day.
  • European shares ended January on a high note, weighed down slightly as investors processed earnings reports and the announcement of new U.S. Fed leadership.
  • Attention now turns to Infineon’s Feb. 4 earnings and what they reveal about auto and silicon-carbide demand.

Infineon Technologies AG shares ended Friday at 41.61 euros, slipping 0.45% after a 3.73% drop the day before.

As the market rests over the weekend, the stock heads into Monday without fresh company updates and just one clear date on investors’ minds. All eyes are on the next earnings report—and the sentiment it will bring.

Europe’s STOXX 600 ended January on a positive note, navigating earnings reports and a shift in US rate outlooks following Donald Trump’s pick of Kevin Warsh to head the Federal Reserve after Jerome Powell’s term concludes in May. Daniel Murray of EFG International called Warsh “credible,” but cautioned that initial signals appear less dovish. Reuters

Tech took the brunt of the pressure. Volatility spiked Thursday amid chatter of a potential U.S. strike on Iran, ongoing budget clashes in Washington, and skepticism about returns from massive AI investments. Analysts at The Carlyle Group noted that bubbles are “endemic to technological revolution.” Reuters

Munich-based Infineon produces semiconductors and system solutions across four divisions, focusing mainly on automotive and power chips.

Infineon is set to release its fiscal first-quarter results on Feb. 4, the company’s investor website confirms.

Before the report, investors are closely watching management’s comments on automotive and silicon carbide demand, according to Simply Wall St’s Jan. 30 note. Silicon carbide, or SiC, is crucial for high-voltage power devices used widely in electric-vehicle drivetrains.

Yet this setup isn’t straightforward. If there’s any sign that carmakers or industrial buyers keep cutting orders or clearing out inventories, the stock could quickly come under pressure—especially if rates shift or risk appetite changes once more.

Following Feb. 4, the next key date is Feb. 19, when Infineon will webcast its annual general meeting starting at 10:00 a.m. CET.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:49 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
KLA stock tumbles on cautious outlook: what to watch before Monday’s open
Previous Story

KLA stock tumbles on cautious outlook: what to watch before Monday’s open

Nanya Technology stock price hits limit-up in Taiwan — equipment buy puts Monday in focus
Next Story

Nanya Technology stock price hits limit-up in Taiwan — equipment buy puts Monday in focus

Go toTop